The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The role of Helicobacter pylori(HP)in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is controversial.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Treatments: Amoxicillin; Azithromycin; Bismuth; Bismuth tripotassium dicitrate; Omeprazole

Criteria

Inclusion Criteria:

• dyspeptic patients with positive antibody to H.pylori and

• persistent elevated aminotransferase levels with the evidence of fatty liver in ultrasonography, who were referred to a gastroenterology clinic.

Exclusion Criteria:

• alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),

• heart disease (ischemic or congestive),

• hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion),

• renal disease (serum creatinine concentration of > 1.5 mg/dl),

• any severe systemic co-morbidities, neoplasm,

• using any hepatotoxic medication during the past 3 months,

• previous history of peptic ulcer,

• previous history of H.pylori eradication,

• existence of alarm signs (weight loss, dysphagia, anemia, vomiting, positive family history of gastrointestinal cancers), and

• pregnant or lactating women.